Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.
Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Coppo P, et al. Among authors: girault s. PLoS One. 2010 Apr 23;5(4):e10208. doi: 10.1371/journal.pone.0010208. PLoS One. 2010. PMID: 20436664 Free PMC article.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
[Bevacizumab therapy for Poems syndrome].
Doffoel-Hantz V, Jaccard A, Sparsa A, Girault S, Bonnetblanc JM, Bordessoule D, Bédane C. Doffoel-Hantz V, et al. Among authors: girault s. Ann Dermatol Venereol. 2008 Apr;135(4):320-1. doi: 10.1016/j.annder.2007.07.008. Epub 2008 Apr 1. Ann Dermatol Venereol. 2008. PMID: 18420085 French. No abstract available.
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, Caillot D, Cornillon J, Dimicoli S, Etienne A, Galicier L, Garnier A, Girault S, Hunault-Berger M, Marolleau JP, Moreau P, Raffoux E, Recher C, Thiebaud A, Thieblemont C, Azoulay E; Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique (GRRR-OH). Darmon M, et al. Among authors: girault s. Br J Haematol. 2013 Aug;162(4):489-97. doi: 10.1111/bjh.12415. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772757 Free article.
L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O. Jaccard A, et al. Among authors: girault s. Ann Oncol. 2009 Jan;20(1):110-6. doi: 10.1093/annonc/mdn542. Epub 2008 Aug 13. Ann Oncol. 2009. PMID: 18701429 Free article. Review.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: girault s. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX. Lippert E, et al. Among authors: girault s. Haematologica. 2010 Sep;95(9):1604-7. doi: 10.3324/haematol.2009.019109. Epub 2010 Apr 30. Haematologica. 2010. PMID: 20435623 Free PMC article.
94 results